Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of hereditary angioedema
Economic burden and healthcare resource utilization
16 evidence topics · 16 sources
Healthcare costs and resource utilization before and after starting long-term prophylaxis: US commercial claims
“A total of 328 patients were included in this analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most patients (67%) had ≥1 post-index on-demand therapy claim.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“During follow-up, 17% and 8% had ≥1 HAE-related ER and inpatient visit, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean annualized total HAE-related healthcare costs per patient were $165,348 pre-LTP and $515,333 post-LTP, driven by increased LTP pharmacy costs (mean $395,845 PPPY) and partially offset by reductions in medical costs (ER/inpatient, mean $8344 PPPY).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study found that 55% of patients had refill gaps in LTP claims, discontinued, or switched LTP within a year of initiation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Healthcare costs with lanadelumab compared with berotralstat: US claims
“Fifty-seven lanadelumab- and 32 berotralstat-treated patients were included.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Total HAE treatment costs were similar during months 0–6 (lanadelumab, $377,326 vs berotralstat, $373,010), but decreased in months 7–12 ($319,967) and 13–18 ($283,241) of lanadelumab.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“On-demand treatment/short-term prophylaxis costs were lower for lanadelumab across the three follow-up periods than for berotralstat during months 0–6 (berotralstat, $60,451; lanadelumab, months 0–6, $46,336, months 7–12, $37,578, months 13–18, $23,968).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“all dollar estimates were inflated to 2022 dollars using the medical care component of the Consumer Price Index.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment costs over time with lanadelumab: US claims
“Fifty-four lanadelumab users were included; 25 (46%) had evidence of down titration.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Lanadelumab costs decreased from $316,724 to $269,861 to $246,919 in months 0-6, 7-12, and 13-18, respectively (p < .01); total HAE treatment costs decreased from $377,076 to $329,855 to $286,074 in months 0-6, 7-12, and 13-18, respectively (p < .01).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Direct and indirect costs of on-demand treatment alone: US patient survey
“Per patient/year direct costs associated with modeled on-demand–only treatment totaled $363,795, with additional indirect socioeconomic costs of $52,576 per patient/year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Medications comprise the largest component (62.5%) of modeled on-demand–only treatment, at an estimated $227,674 per patient per year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The second highest component cost was hospitalization for treatment of an HAE attack (22.1%), followed by ED visits (12.5%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Annual per-patient costs by attack severity before current prophylactic agents: US patient survey
“Total annual per-patient costs are estimated at $42,000 for the average HAE patient, with costs totaling $14,000 for patients with mild attacks, $27,000 for patients with moderate attacks, and $96,000 for patients with severe attacks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Hospital costs account for 67% of direct medical costs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Respondents reported high rates of missed work, lost productivity, and lost income, contributing to indirect costs totaling $16,000 annually for the average patient.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Resource use after insurance delays or denials of prophylaxis
“A total of 70% of participants reported an increased frequency of angioedema attacks resulting from insurance delays or denials.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Twenty-five percent of respondents reported more urgent care or emergency department visits.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
On-demand drug costs per member before and after starting long-term prophylaxis: US commercial claims
| Population | Allowed cost per member, pre-LTP | Allowed cost per member, post-LTP | Change in allowed cost per member | Percent change |
|---|---|---|---|---|
| On-demand therapy experienced cohort (N = 29) | “$108,748” | “$61,390” | “-$47,358” | “-43.6%” |
Cost per attack treated on demand: Italian prospective cohort
“To explore treatment behaviours in a cohort of Italian patients with hereditary angioedema due to complement C1-inhibitor deficiency (C1-INH-HAE), and to estimate how effects and costs of treating attacks in routine practice differed across available on-demand treatments.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cost analyses and survival analyses using attack-level data collected prospectively for 1 year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 133 of 167 patients (79.6%) reported 1508 attacks during the study period, with mean incidence of 11 attacks per patient per year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Only 78.9% of attacks were treated in contrast to current guidelines.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The average cost per attack was €1183 (SD €789) resulting in €1.58 million healthcare costs during the observation period (€11 912 per patient per year).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Icatibant was 54% more expensive than pdC1-INH, whereas age, sex and prophylactic treatment were not associated to higher or lower costs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Modeled cost per attack of on-demand treatments: US commercial payer decision model
“To estimate the cost-effectiveness of on-demand treatment for HAE attacks, a decision-tree model from the U.S. commercial payer perspective was developed using TreeAge Pro 2018 R1 release” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All costs are dated to 2019, either directly or by inflation using the medical-care inflation subset of the Consumer Price Index for All Urban Consumers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The base case model outputs show costs and calculated effectiveness per attack at $12,905 and 0.806 for rhC1-INH, $14,806 and 0.765 for icatibant, $14,668 and 0.769 for pdC1-INH, and $21,068 and 0.792 for ecallantide, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Emergency department and hospital use among users of intravenous C1 inhibitor: US claims
“The purpose of this retrospective study was to evaluate real-world treatment patterns of HAE-specific medications in the US and to assess their impact on healthcare resource utilization (HCRU).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This analysis used IMS PharMetrics PlusTM database records (2006–2014) of patients with HAE, ≥1 insurance claim for an HAE-specific medication, and continuous insurance enrollment for ≥3 months following the first HAE prescription claim.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of 631 total patients, 434 (68.8%) reported C1-INH(IV) use; 396 (62.8%) reported using ecallantide and/or icatibant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were 306 episodes of prophylactic use of C1-INH(IV) (defined by continuous refills averaging ≥1500 IU/week for ≥13 weeks) in 155 patients; use of ≥1 on-demand rescue medication was implicated during 53% (163/306) of those episodes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Sixty-eight (20.2%) of 336 C1-INH(IV) users eligible for the HCRU analysis were hospitalized at least once, and 191 (56.8%) visited the emergency department (ED).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study was funded by CSL Behring.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Emergency department visits with hereditary angioedema: Nationwide Emergency Department Sample, 2006 to 2007
“We evaluated epidemiology, resource use, and discharge destinations of HAE (International Classification of Diseases, Version 9, clinical modification [ICD-9-CM] code 277.6) ED visits within the Nationwide Emergency Department Sample, part of Agency for Healthcare Research and Quality Healthcare Costs and Utilization Project, in 2006 and 2007.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In 2006-2007, there were 5040 ED visits with HAE, of which 2705 (53.7%) had HAE as the principal diagnosis (HAE-PD).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Two thousand fifty-nine (40.9%) resulted in a hospitalization.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Mean HAE ED visits costs were $1479 (95% confidence interval, $1028-1929).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Hospitalizations and emergency department visits with hereditary angioedema: nationally representative inpatient and emergency department samples, 2007
“We examined hospitalizations and ED utilization for HAE and AE in two large nationally representative databases.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We also used AHRQ-HCUP's 2007 Nationwide Emergency Department Sample (NEDS) to study annual rates of ED visits and subsequent hospitalizations with these conditions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“There were 1691 hospitalizations with HAE and 22,572 with AE (4.25 HAE and 57.08 AE cases/100,000 hospitalizations).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In aggregate, HAE and AE PD hospitalizations accrued 35,000 hospital days and hospital costs of $63 million.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“There were 2282 ED visits with HAE and 112,105 ED visits with AE (1.87 HAE and 91.64 AE cases/100,000 ED visits).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Forty-five percent of HAE patients and 18.3% of AE patients required hospitalization.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Attack-related medical visits and provider-administered on-demand treatment before and after berotralstat: US claims
“To evaluate all-cause, angioedema-related, and HAE attack–related medical visits and hospitalizations before and after initiation of berotralstat long-term prophylaxis (LTP) for patients with HAE in the United States.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This retrospective pre-post analysis used Komodo’s Healthcare Map claims data to identify patients who initiated berotralstat (December 2020 to December 2022).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The study population included 260 patients treated with berotralstat (mean age = 39.7 years; 74.2% female).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“When stratifying by type of care setting, rates of HAE attack–related IP episodes decreased by 60% (from 0.28 to 0.11 PPY, P < 0.001) and OP/ED episodes decreased by 50% (from 1.46 to 0.74 PPY, P < 0.001) after berotralstat initiation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Following berotralstat initiation, the rates of on-demand medication administered by a provider decreased significantly by 32% (from 1.17 to 0.87 PPY, P = 0.002) among all patients” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Medical writing assistance was provided by Molly Gingrich, an employee of Groupe d’Analyze, Ltée, which received funding from BioCryst Pharmaceuticals for this study” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Medical care, activity loss, and missed work or school: European patient survey
“The study was conducted in Spain, Germany, and Denmark to assess the real-world experience of HAE via a cross-sectional survey of HAE patients, including direct and indirect resource utilization during and between attacks for patients and their caregivers over the past 6 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 164 patients had an attack in the past 6 months and were included in the analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most significant predictor of medical resource utilization was the severity of the last attack (OR 2.6; p < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among patients who sought medical care during the last attack (23%), more than half utilized the emergency department.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The last attack prevented patients from their normal activities an average of 4–12 hours.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among patients who were working or in school (n = 120), 72 provided work/school absenteeism data, resulting in an estimated 20 days missing from work/school on average per year; 51% (n = 84) indicated that HAE has hindered their career/educational advancement.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The study was funded by ViroPharma SPRL-BVBA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Societal costs: Dutch patient survey
“Adult patients with HAE under treatment at the Dutch national center of reference completed a cross-sectional survey in 2021.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The response rate was 78% (69 of 88).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“On average, total costs per year incurred €22,764, predominantly existing of HAE-medication costs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Total costs showed substantial variation between patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote